In 2025, dermatology continued its evolution into one of medicine’s most dynamic and interdisciplinary fields. No longer confined to treating visible disease alone, dermatology increasingly addressed systemic inflammation, mental health, technology integration, aesthetics, and global public health. Across conferences and expert conversations, a common message emerged: progress now depends on precision, safety, and meaningful patient outcomes rather than novelty for novelty’s sake.
Inflammatory skin disease remained a focal point of innovation. Raj Chovatiya, MD, PhD, MSCI, emphasized that conditions such as chronic hand eczema and atopic dermatitis demand better phenotyping and long-term strategies rather than episodic treatment. Improved epidemiologic data and disease recognition, he noted, are helping clinicians identify patients earlier and tailor therapy more effectively. That need for personalization was echoed by Jonathan Silverberg, MD, PhD, MPH, who highlighted how emerging biologics and targeted therapies are changing expectations for itch relief, disease control, and quality of life in atopic dermatitis.
As the therapeutic armamentarium expanded, clinicians increasingly questioned rigid treatment algorithms. Scott Boswell, MD, urged providers to abandon “monotherapy thinking,” explaining that inflammatory skin diseases often require layered approaches that reflect complex immune signaling rather than a single dominant pathway. Similarly, Christopher Bunick, MD, PhD, underscored that newer upstream targets—such as OX40 and OX40L—may eventually complement or reshape current biologic strategies, pending long-term data.
Safety considerations shaped nearly every discussion, particularly in pediatric dermatology. Peter Lio, MD, stressed that while therapeutic advances have been impressive, children remain underserved, especially those under 12 years of age. He highlighted the emotional and logistical toll pediatric eczema places on families and emphasized cautious prescribing, steroid stewardship, and the growing importance of nonsteroidal options. That momentum continued with expanding pediatric approvals, which Nicole Harter, MD, described as a turning point for younger patients who previously had limited long-term treatment choices.
Beyond eczema, alopecia areata represented another area of significant progress. Vimal Prajapati, MD, FRCPC, DABD, reviewed how selective JAK inhibition is restoring hair growth for patients with severe disease, while also requiring careful monitoring and patient education. These advances, he noted, underscore the importance of balancing efficacy with safety and shared decision-making.
Technology continued to influence how dermatology is practiced. Artificial intelligence emerged less as a disruptive force and more as a clinical support tool. Thazin Aung, PhD, explained how AI-assisted melanoma scoring systems can improve consistency and reduce variability while preserving clinician oversight. From a workflow perspective, Jon Friis highlighted how generative AI may streamline documentation and administrative tasks, allowing clinicians to devote more time to patient care rather than screens.
Equity and access remained persistent challenges. Mondana Ghias, MD, FAAD, emphasized that teledermatology and diverse provider representation are essential to improving diagnostic accuracy and access for patients with skin of color. On a global scale, Claire Fuller, MA, FRCP, framed dermatologic disease as a public health issue, pointing to international policy efforts that aim to integrate skin health into broader health systems and close long-standing care gaps worldwide.
Aesthetic dermatology in 2025 increasingly aligned itself with regenerative science and long-term skin health. Robin Smith, MD, MBA, described how exosome-based technologies are shifting patient demand away from short-term cosmetic fixes toward biologically driven regeneration. This philosophy reflects a broader trend in which aesthetics and medical dermatology are no longer viewed as separate domains, but as complementary aspects of skin longevity.
Scientific rigor remained critical as regenerative technologies gained popularity. Prithwiraj Maitra, PhD, cautioned that exosome and secretome-based products must be backed by stability data, transparency, and reproducible science to earn clinician trust. He emphasized that regenerative aesthetics will only succeed long-term if claims are grounded in validated biology rather than marketing narratives.
Incremental innovation also played an important role. In neurotoxin therapy, Rosalyn George, MD, highlighted how refinements in onset time and consistency are improving patient satisfaction without altering fundamental safety profiles. Meanwhile, systemic trends such as widespread GLP-1 agonist use introduced new aesthetic considerations. Joely Kaufman, MD, noted that dermatologists are increasingly managing secondary cosmetic concerns such as facial volume loss, requiring proactive conversations and treatment planning.
Psychodermatology gained overdue attention in 2025. Sofia Wenzler, PhD, addressed persistent misconceptions surrounding dermatillomania and trichotillomania, advocating for compassionate, multidisciplinary care that recognizes these conditions as body-focused repetitive behaviors rather than bad habits. Similarly, Adam Friedman, MD, reframed chronic itch as a diagnostic signal that often reflects systemic or neurologic dysfunction, rather than a mere symptom to suppress.
Looking ahead, experts agreed that dermatology’s future lies in integration. Brian Kim, MD, MTR, FAAD, emphasized that understanding inflammation as a unifying mechanism across multiple skin diseases can unlock new therapeutic insights. At the same time, Massimo Gadina, PhD, highlighted the potential for genetics-guided treatment selection to improve specificity and outcomes in inflammatory disease.
By the end of 2025, dermatology stood defined not by a single breakthrough, but by its expanding scope and responsibility. The specialty continued to blend innovation with empathy, technology with clinical judgment, and aesthetics with ethics. As therapies grow more powerful and precise, the challenge for clinicians will be not simply to adopt what is new, but to apply it thoughtfully for the diverse patients who depend on dermatologic care at every stage of life.
Thank you!
Our team would like to extend our heartfelt thanks to all the experts who generously shared their insights with Dermatology Times over the past year. Your dedication, expertise, and willingness to engage in candid discussions have helped advance the field, inspire innovation, and ultimately improve patient care. From groundbreaking research to practical clinical guidance, your contributions continue to shape the future of dermatology and strengthen the community of clinicians, researchers, and patients alike.
